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ABSTRACT: 
BACKGROUND: Mutations in RBM20 cause a clinically aggressive form of dilated cardiomyopathy (DCM), 
with an increased risk of malignant ventricular arrhythmias. RBM20 is a splicing factor that targets 
multiple pivotal cardiac genes, such as Titin (TTN) and Calcium/calmodulin-dependent kinase II delta 
(CAMK2D). Aberrant TTN splicing is thought to be the main determinant of RBM20-induced DCM, but is 
not likely to explain the increased risk of arrhythmias. Here, we investigated the extent at which RBM20 
mutation carriers have an increased risk of arrhythmias and explore the underlying molecular 
mechanism. 
METHODS: We compared clinical characteristics of RBM20 and TTN mutation carriers and used our 
previously generated Rbm20 knockout (KO) mice to investigate downstream effects of Rbm20- 
dependent splicing. Cellular electrophysiology and Ca2+ measurements were performed on isolated 
cardiomyocytes from Rbm20 KO mice to determine the intracellular consequences of reduced Rbm20 
levels. 
RESULTS: Sustained ventricular arrhythmias were more frequent in human RBM20 mutation carriers 
than in TTN mutation carriers (44% vs 5%, respectively, p=0.006). Splicing events that affected Ca2+ and 
ion handling genes were enriched in Rbm20 KO mice, most notably in the genes CamkIIδ and RyR2. 
Aberrant splicing of CamkIIδ in Rbm20 KO mice resulted in a remarkable shift of CamkIIδ towards the δ-A 
isoform which is known to activate the L-type Ca2+ current (ICa,L). In line with this, we found an increased 
ICa,L, intracellular Ca2+ overload and increased sarcoplasmic reticulum (SR) Ca2+ content in Rbm20 KO 
myocytes. Additionally, not only complete loss of Rbm20, but also heterozygous loss of Rbm20 increased 
spontaneous SR Ca2+ releases, which could be attenuated by treatment with the ICa,L antagonist 
verapamil. 
CONCLUSIONS: We show that loss of Rbm20 disturbs Ca2+ handling and leads to more pro-arrhythmic 
Ca2+ releases from the SR. Patients that carry a pathogenic RBM20 mutation have more ventricular 
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arrhythmias despite a similar LV function, compared to patients with a TTN mutation. Our experimental 
data suggests that RBM20 mutation carriers may benefit from treatment with an ICa,L blocker to reduce 
their arrhythmia burden. 
 
 








What is new? 
 
• Patients that carry a pathogenic RBM20 mutation have more ventricular  arrhythmias  than 
patients with a TTN mutation, despite similarly depressed LV function. 
• Targets of RBM20 splicing are enriched for Ca2+ and ion handling genes, most notably CamkIIδ 
and RyR2. 
• Loss of Rbm20 induces an increased L-type Ca2+ current density, intracellular Ca2+ overload, 
increased SR Ca2+ content, and increased spontaneous Ca2+ releases, which can be attenuated by 
treatment with an L-type Ca2+ channel blocker. 
What are the clinical implications? 
 
• RBM20 mutation carriers may benefit from treatment with an ICa,L blocker to reduce their 
arrhythmia burden. 
• RBM20 mutation carriers should be closely monitored for potential electrical disturbances and 




Mutations in the gene encoding RNA-binding motif protein 20 (RBM20) are known to cause dilated 
cardiomyopathy (DCM)1-3. In fact, disease-causing mutations in RBM20 are relatively often found in 
familial DCM, as it accounts for about 3% of the familial DCM cases4. Recent studies suggest that loss of 
RBM20 causes DCM by missplicing of the gene Titin (TTN)5, 6. TTN is a giant sarcomeric protein which acts 
as a molecular spring in the sarcomere, and as such, defines the passive stiffness of the cardiomyocyte. 
Loss of Rbm20 leads to aberrant splicing of TTN, reflected by increased expression of very large and 
compliant TTN isoforms in the heart, which is believed to underlie the DCM phenotype in RBM20 
mutation carriers. However, clinical observations challenge the idea that mutations in RBM20 cause DCM 
only via dysfunctional TTN. RBM20 mutation carriers are known to present with a clinically aggressive 
form of DCM, associated with young age at diagnosis, fast progression of heart failure, increased risk of 
arrhythmias, and high mortality1, 2, 4, while TTN mutations are not associated with such an aggressive 
clinical course7, 8. 
 
RBM20 is a heart- and skeletal muscle-enriched splicing factor which controls tissue-specific isoform 
expression of many other genes besides TTN, including sarcomeric genes such myomesin 1, but also Ca2+ 
and ion handling genes such as calcium/calmodulin-dependent kinase II-delta (CAMK2D) and Ryanodine 
Receptor 2 (RYR2)5, 6. In that regard, it is of interest that human RBM20 mutation carriers present with an 
increased risk of arrhythmias, which is also observed in Rbm20 deficient rats4, 5. Taken together, this 
indicates that the missplicing of TTN alone is unlikely to fully explain the severe heart failure phenotype 
found in RBM20 mutations carriers, and that additional Rbm20 targets may be of clinical importance. 
Indeed, in vitro analysis of cardiomyocytes derived from induced pluripotent stem cells of an RBM20 
mutation carrier recently provided the first evidence that Rbm20 regulates Ca2+ handling9. 
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Here we investigated the underlying mechanism of arrhythmias in RBM20 mutation carriers, by using 
Rbm20 knockout (KO) mice and performing electrophysiological studies and Ca2+ measurements. We 
recorded L-type Ca2+ current (ICa,L) in wildtype and Rbm20 KO cardiomyocytes, and found an almost 2- 
fold increase in current density. Ca2+ measurements revealed a severe intracellular Ca2+ overload, and a 
propensity to spontaneous Ca2+ releases from the sarcoplasmic reticulum (SR) in both heterozygous and 
homozygous Rbm20 KO cardiomyocytes. Blockade of ICa,L with verapamil rescued the Ca2+ releases from 
the SR, indicating that increased ICa,L density is, at least in part, responsible for Ca2+ overload in Rbm20 KO 
cells. Our data indicates that this disturbed Ca2+ handling induced by dysfunctional Rbm20 underlies the 
increased risk of arrhythmias in RBM20 mutation carriers, and therefore this study provides new avenues 





The data, analytic methods, and study materials will be made available upon reasonable request to other 
researchers for purposes of reproducing the results or replicating the procedure. Extended methods are 





The genetic test results of all patients with (suspected) DCM who were referred to the Department of 
Clinical Genetics of the Academic Medical Center (Amsterdam, Netherlands) between 2005 and 2016 
were retrospectively reviewed. All patients with a (likely) pathogenic variant in the RBM20 gene (n=18) 
or the TTN gene (n=22) and no other variants in genes associated with DCM were included. Additional 
information on patient inclusion can be found in Supplemental File 1, and the mutations included in this 
study can be found in Supplemental Table 1. Informed consent was obtained from all individuals and the 
study confirmed to the ethical guidelines of the 1975 Declaration of Helsinki. 
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Rbm20 KO mice 
 
Rbm20 KO mice were previously generated10. All animal studies were approved by the Institutional 
Animal Care and Use Committee of the University of Amsterdam, and in accordance with the guidelines 





Left ventricular cardiomyocytes from 8 to 12-week old wildtype (WT), heterozygous (+/-), and 
homozygous (-/-) Rbm20 KO mice were isolated by enzymatic dissociation on a Langendorff set-up, 
loaded with the Ca2+ sensitive dye Indo-1-AM (Molecular Probes, Eugene, OR, USA), and Ca2+ transients 




Action potentials (APs) and ICa,L were recorded in isolated left ventricular (LV) cardiomyocytes from 8 to 
12-week old WT and Rbm20 KO mice at 36±0.2°C using an Axopatch 200B amplifier (Molecular Devices, 
Sunnyvale, CA, USA). Voltage control, data acquisition, and analysis were realized with custom software, 
and potentials were corrected for the calculated liquid junction potentials12. Cell membrane capacitance 
(Cm) was calculated by dividing the time constant of the decay of the capacitive transient after a -5 mV 
voltage step from –40 mV by the series resistance. Signals were low-pass-filtered with a cutoff of 5 kHz 





Data are presented as mean ± sem, and were analyzed with appropriate statistical tests, as indicated in 




Increased prevalence of malignant ventricular arrhythmias in RBM20 mutation carriers 
 
Patients with heterozygous RBM20 mutations present with DCM, but often also experience cardiac 
arrhythymias. We compared arrhythmia burden of DCM patients with RBM20 mutations (n=18) to DCM 
patients with TTN mutations (n=22) (Table 1). Since TTN is the most prominently studied target of 
RBM20, and is considered the main determinant of the DCM phenotype of RBM20 mutation carriers, we 
used DCM patients with TTN mutations as a reference group. Both groups had similarly decreased LV 
chamber function (LVEFRBM20vsTTN; 37±17 vs 37±13), dilation of the LV (LVEDDRBM20vsTTN; 60±11 vs 59±9 and 
LVEDVRBM20vsTTN; 269±92 vs 246±73), and similar ECG timing intervals (Table 1). Despite comparable 
cardiac function and remodeling in both patient groups, RBM20 mutation carriers experienced more 
malignant ventricular arrhythmias, as 44% of the RBM20 mutation carriers had sustained ventricular 
arrhythmias (i.e. sustained/symptomatic ventricular tachycardia or ventricular fibrillation), compared to 
only 5% in the TTN group (p=0.006). The increased risk of arrhythmias was also reflected by the 
increased number of ICD implantations in the RBM20 group (ICDRBM20vsTTN; 61% vs 9%, p=0.002). There 
were no differences in the pharmacological treatment of patients with RBM20 mutations and patients 
with TTN mutations. Finally, RBM20 mutation carriers tended to have more often a familial history of 
sudden cardiac death (SCD) (SCDRBM20vsTTN; 72% vs 36%, p=0.052). In conclusion, these data indicate that 
patients with RBM20 mutations have an increased risk of malignant ventricular arrhythmias as compared 
to TTN mutation carriers, even though cardiac dilation and function is comparable in both patients 
groups. This also suggests that the cardiac pathology of RBM20 mutation carriers is only partly explained 
by altered TTN function, and that other factors contribute to the arrhythmia susceptibility. 
 
 
Characterization of Rbm20 KO mice 
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In order to investigate the molecular mechanisms underlying the increased risk of arrhythmias in RBM20 
mutation carriers, we used Rbm20 KO mice that were previously generated by targeted disruption of 
exon 4 and 5 of the Rbm20 gene (Figure 1A)10. Rbm20 KO mice were born in normal Mendelian ratios, 
were viable, and did not exhibit obvious abnormalities. We validated the loss of the targeted Rbm20 
allele by qPCR (all primer sequences can be found in Supplemental Table 2), and observed an 
approximate 50% reduction of Rbm20 mRNA in Rbm20+/- hearts and a complete loss of Rbm20 mRNA in 
Rbm20-/- hearts (Figure 1B). qPCR analysis of the stress markers ANF and BNP revealed an upregulation 
of both markers in the hearts of Rbm20-/- mice, but not in Rbm20+/- mice (Figure 1C-D). Loss of Rbm20 
resulted in disrupted splicing of Ttn and LIM-domain Binding 3 (Ldb3) in the hearts Rbm20+/- and 
Rbm20-/- mice (Figure 1E). This recapitulates previously described splicing effects of Rbm20-deficiency in 
mice and rats5, 13. Next, we investigated cardiac function and morphology of these mice. Heart 
weight/body weight ratios were not different between wildtype, Rbm20+/-, and Rbm20-/- mice (Figure 
1F), but M-mode echocardiography revealed decreased fractional shortening and increased systolic 
diameters in both Rbm20+/- and Rbm20-/- mice, indicative of a cardiomyopathic phenotype (Figure 1G- 
I). Surface electrocardiograms (ECG) showed a prolonged PR and QTc interval in Rbm20-/- mice, starting 
at 6 weeks of age, which remained until at least 25 weeks of age (Figure 1J-K). No difference in QRS 
duration and RR interval were observed (Supplemental Figure 1). The differences between 6 and 8 weeks 
can be explained by growth and maturation of the mice. Rbm20-/- hearts showed moderate fibrosis, as 
was evidenced by Sirius Red stained sections of the hearts of 25 weeks old mice (Figure 1L-M). 
Consistently, the expression of collagen 1a1 and collagen 3a1 mRNA was increased in Rbm20-/- hearts 
(Supplemental Figure 2). In summary, Rbm20 KO mice develop cardiomyopathy, have ECG abnormalities, 
increased cardiac fibrosis, and disturbed splicing of previously described Rbm20-targets. 
 
 
Rbm20 KO mice display splicing abnormalities in Ca2+ and ion handling genes 
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To uncover splicing targets of Rbm20 that could explain the increased risk of arrhythmias in RBM20 
mutation carriers, we used next-generation RNA-sequencing on wildtype and Rbm20-/- mice, 25 weeks 
of age, and analyzed their transcriptomes on differential splicing events using DEXseq14. Gene ontology 
enrichment analysis on the differentially spliced genes revealed that genes involved in ‘cardiac muscle 
contraction’ were enriched in the hearts of Rbm20-/- mice (Supplemental File 2). Interestingly, genes in 
the biological process ‘cardiac muscle contraction’ encompass two types of genes; sarcomeric genes, 
such as Ttn, Tnnt2, and Myh6/7, and Ca2+ and ion handling genes, such as Slc8a1, RyR2, and CamkIIδ 
(Figure 2A). We validated the differential splicing events using endpoint RT-PCR in wildtype, Rbm20+/-, 
and Rbm20-/- mice, and were able to verify the splicing changes in CamkIIδ, RyR2, Scn5a (which encodes 
the cardiac Na+ channel NaV1.5), and Cacna1c (which encodes the L-type calcium channel subunit 
CaV1.2) (Figure 2B, Supplemental Figure 3A-C). 
 
 
The atypical splicing of CamkIIδ in the Rbm20 KO hearts is particularly relevant for cardiomyocyte 
biology. CamkIIδ is a multifunctional Ser/Thr protein kinase and is an important regulator of excitation- 
contraction coupling by phophorylation of its substrates phopholamban (PLB), the ryanodine receptor 
(RyR), and the L-type Ca2+ channel (LTCC)15-17. CamkIIδ exists in multiple isoforms in the adult heart, most 
notably δ-A, δ-B, δ-C, and δ-918. In the healthy adult heart, the highest expressed isoforms are δ-B and δ- 
C, but loss of Rbm20 induced a switch towards the bigger δ-A and δ-9 mRNA isoforms (Figure 2B). The 
smallest isoform, δ-C lacks all alternative exons, and is located in the cytoplasm where it has been shown 
to phosphorylate RyR2 and PLB15. In the δ-B isoform, exon 14 with a functional nuclear localization signal 
is spliced into the transcript, thereby targeting CamkIIδ to the nucleus, where it specifically associates 
with histone deacetylases to regulate transcription19, 20. The δ-A isoform results from inclusion of exon 15 
and 16, and is associated with the intercalated disc and T-tubules, where Ca2+ channels and activated 
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CamKIIδ are concentrated16, 21. The exact function of δ-9 is currently unknown, but as it is the isoform 
that resembles δ-A the most (it only lacks exon 15), it likely fullfils a similar function as δ-A. 
The nearly complete switch of CamKIIδ to the δ-A isoform led us to investigate the consequences of 
aberrant splicing on CamKIIδ expression and localization in the Rbm20 KO hearts. Western blotting 
further provided evidence of the isoform switch, as we detected a larger CamKIIδ protein in Rbm20+/- 
and Rbm20-/- hearts (Figure 2C, Supplemental Figure 3E). We did not find a difference in overall mRNA 
expression of CamkIIδ in wildtype, Rbm20+/-, and Rbm20-/- mice (Supplemental Figure 3D). We 
performed immunohistochemistry on sections of wildtype and Rbm20-/- hearts and found that CamkIIδ 
colocalizes with the LTCC in the t-tubules, as indicated by costaining with Cacnb1 (Figure 2D, and 
supplemental Figure 4). We did not find increased CamkIIδ localization in the t-tubules in Rbm20-/- 
hearts as compared to wildtype hearts, but this difference might be subtle and not readily identifiable 
with immunostainings. Interestingly, we detected increased expression of CamKIIδ in the intercalated 
discs of Rbm20-/- cardiomyocytes, again indicating a switch to the δ-A isoform21. Since the switch in 
CamkIIδ isoform could potentially impact phosphorylation targets of CamkIIδ, we performed western 
blotting for phosphorylated RyR2 (at Serine 2815) and phosphorylated Cacnb2 (at Threonine 498) in 
Rbm20-/- hearts. In both cases, we did not observe a difference in phosphorylation status at these 
specific amino acids (Supplemental Figure 5). 
 
 
The differential splicing event in RyR2 involves inclusion of a 24-bp exon, which targets RyR2 to the 
nucleus instead of the SR, which may interfere with proper Ca2+ handling22. The splicing change that we 
observed in Scn5a represents alternative first exon usage with yet unknown significance23. The splicing 
change in Cacna1c, which encodes a subunit of the LTCC, in Rbm20 -/- hearts represents the inclusion of 
exon 9*, and this splicing event has been associated with hyperpolarization of the LTCC24. With respect 
to the differential splicing events in Slc8a1 (Ncx1), we found increased inclusion of exon 2A, indicative of 
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increased expression of the NCX1.1 splice variant25. The increased expression of the NCX1.1 splice variant 
could indicate that Na+-dependent inactivation of NCX is reduced25, but the functional consequences in 
Rbm20 KO hearts are unclear. 
 
 
To rule out that the differential splicing events are not secondary to the DCM, but due to loss of Rbm20, 
we used GapmeRs to knockdown Rbm20 in neonatal rat cardiomyocytes (NRCM), which resulted in a 
~80% decrease in Rbm20 mRNA expression (Figure 2E). Using endpoint RT-PCR we observed similar 
splicing changes in Ttn, CamkIIδ, and RyR2 as in the Rbm20 KO hearts (Figure 2F). These in vitro data 
indicate that Rbm20 directly regulates alternative splicing of TTN, CamKIIδ and RyR2 and that these 
isoform switches are not secondary to the DCM. 
 
 
To investigate whether these Rbm20-dependent splicing changes also occur in human RBM20 mutation 
carriers we made use of an RNAseq dataset of a previously described DCM patient with a heterozygous 
RBM20 (p.E913K) mutation that we compared to an idiopathic DCM patient and 10 healthy individuals26, 
27. We calculated the percentage-spliced-in (PSI) of the alternative exons and found that also in this 
 
RBM20 mutation carrier, but not in the DCM patient, alternative splicing of CAMK2D and RYR2 was 
similarly affected (Figure 2G, Supplemental Figure 6). We did not observe splicing differences in SCN5A 
and CACNA1C in the RBM20 patient compared to the DCM patient (data not shown). 
 
 
With respect to the CAMK2D splicing in the human RBM20 mutation carrier, it is remarkable that δ-9 was 
greatly induced, and not δ-A, as we found in the Rbm20 KO mice and in NRCM with reduced Rbm20 
levels. Indeed, it was shown earlier that exon 15 (included in δ-A, but excluded in δ-9) is hardly expressed 
in human heart5, 6. In conclusion, these data reveal splicing abnormalities in Ca2+ and ion handling genes 
such as CamkIIδ and RyR2 after loss of Rbm20 in human, rat, and mouse. 
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The L-type Ca2+ current (ICa,L) is increased in Rbm20 KO myocytes 
 
To investigate whether the splicing abnormalities in CamKIIδ and Cacna1c in Rbm20-/- hearts would 
affect ICa,L and APs, we performed patch-clamp electrophysiological studies in isolated cardiomyocytes of 
8 to 12-week old mice, representing the early phase in the development of the cardiomyopathy. We 
found that the action potential duration at 90% of repolarization (APD90) was prolonged in Rbm20-/- 
cardiomyocytes by approximately 50% (Figure 3A-B). The upstroke of the AP, as indicated by the Vmax and 
AP amplitude (APA), and the resting membrane potential (RMP) were not signficantly different (Figure 
3C-D). Since the AP duration is importantly regulated by ICa,L and since the isoform switch of CamkIIδ is 
expected to increase the activity of the LTCC, we recorded ICa,L. Figure 3E shows representative ICa,L 
recordings upon a depolarizing step from -60 to 0 mV, and the right panel shows the same recordings  
but scaled to the ICa,L of wildtype cardiomyocytes. ICa,L was significantly larger in Rbm20 -/- 
cardiomyocytes, and inactivation was faster, as analyzed with biexponential fits. Time constants of both 
fast and slow inactivation were significantly lower in Rbm20-/- cardiomyocytes (τs: 31.7 ± 3.4 vs 22.2 ± 
1.4 ms; τf : 5.6 ± 0.5 vs 3.2 ± 0.2 ms). Most strikingly, the average current-voltage (I-V) relationships were 
significantly larger (~82% at 0 mV) in Rbm20-/- cardiomyocytes (Figure 3F). Neither voltage-dependency 
of activation nor voltage-dependency of inactivation were different between wildtype and Rbm20-/- 
cardiomyocytes (Figure 3G). The increase in ICa,L density and action potential duration could not be 
explained by altered expression of Ncx or Cacna1c (Supplemental Figure 5). In conclusion, Rbm20-/- 
cardiomyocytes display increased ICa,L density, resulting in AP prolongation. 
 
 
Rbm20 KO cardiomyocytes exhibit intracellular Ca2+ overload and are prone to spontaneous SR Ca2+ 
releases 
To investigate whether the increased ICa,L in Rbm20 KO cardiomyocytes further leads to Ca2+ handling 
 
abnormalities, we analyzed Ca2+ transients in isolated 8 to 12-week old wildtype, Rbm20+/-, and  Rbm20- 
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/- cardiomyocytes at 2, 4, and 6 Hz of field stimulation. We found that both Rbm20+/- and Rbm20-/- 
cardiomyocytes exhibit remarkably large Ca2+ transients, and this was most pronounced at 6 Hz 
(Supplemental Figure 7). Figure 4A shows representative Ca2+ transients of a wildtype, Rbm20+/-, and 
Rbm20-/- cardiomyocyte at 6 Hz of stimulation. Diastolic Ca2+ was increased ~2-fold (Diastolic 
Ca2+WTvsHETvsKO: 79.9 ± 7.3 vs 184.4 ± 22.1 vs 163 ± 11.9 nM) and the peak amplitude was increased ~3-fold 
(Peak amplitudeWTvsHETvsKO: 101 ± 10.5 vs 333.9 ± 60.8 vs 308.9 ± 58.8 nM) in Rbm20+/- and Rbm20-/- 
cardiomyocytes (Figure 4A-C). Next, we examined SR Ca2+ content by rapid cooling and found that it was 
increased ~3.5-fold in Rbm20+/- and Rbm20-/- cardiomyocytes (SR Ca2+ WTvsHETvsKO: 214.4 ± 21.3 vs 791.8 ± 
170.7 vs 690.8 ± 79.7 nM) (Figure 4D, representative traces in Supplemental Figure 8). Both increased SR 
Ca2+ content and elevated diastolic Ca2+ increase the open probability of the RyR-channels, resulting in an 
increase of spontaneous SR Ca2+ releases, which in turn can trigger delayed after depolarizations (DADs) 
that are pro-arrhythmic28. To examine spontaneous SR Ca2+ releases, we stopped stimulation (6 Hz) of 
cardiomyocytes, after which spontaneous activity was recorded for 10 seconds. At baseline, both 
Rbm20+/- and Rbm20-/- cardiomyocytes showed more spontaneous Ca2+ releases than wildtype 
cardiomyocytes, and this effect was exacerbated after application of 50 nM noradrenaline (Figure 4E, 
representative traces in Supplemental Figure 9). In conclusion, out data shows that Rbm20 KO 
cardiomyocytes display Ca2+ overload, increased SR Ca2+ content, and more spontaneous Ca2+ releases, 
especially after β-adrenergic stimulation. Interestingly, Ca2+ handling was as severely affected in 
Rbm20+/- as in the Rbm20-/- cardiomyocytes. 
 
 
Inhibition of L-type Ca2+ current with verapamil decreases pro-arrhythmic spontaneous Ca2+ releases 
Since we suspect that the increased ICa,L underlies the increased intracellular Ca2+ levels, the SR Ca2+ 
overload, and the spontaneous Ca2+ releases in the Rbm20 KO cells, we hypothesized that inhibiting ICa,L 
with  verapamil,  a  well-known  LTCC-antagonist,  would  decrease  the  number  of  spontaneous  Ca2+ 
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releases. We incubated Rbm20-/- cardiomyocytes with 1 µM verapamil, a concentration that has been 
shown to decrease ICa,L by approximately 30%29, and again recorded spontaneous Ca2+ releases. Strikingly, 
incubation of Rbm20-/- cardiomyocytes with verapamil decreased the number of spontaneous Ca2+ 
releases after the addition of noradrenaline to wildtype levels (Figure 4E, and Supplemental Figure 9). 
These data indicate that the increased ICa,L, at least in part, contributes to pro-arrhythmic SR Ca2+ releases 
in Rbm20-/- cardiomyocytes. Moreover, our results indicate that treatment of RBM20 mutation carriers 
with the LTCC-antagonist verapamil might prove beneficial to decrease the number of malignant 
ventricular arrhythmias that RBM20 mutation carriers experience. Figure 5 depicts the proposed model 




This study shows that RBM20 mutation carriers have more severe ventricular arrhythmias than TTN 
mutation carriers, despite equally severe DCM. This suggests that other mechanisms besides missplicing 
of TTN may contribute to the aggressive clinical course of RBM20-induced DCM. We addressed whether 
this relates to missplicing of Ca2+ handling genes. We investigated this in Rbm20 KO mice, and revealed 
that Rbm20 KO cardiomyocytes have severely disturbed Ca2+ handling, with increased Ca2+ transients, 
increased diastolic Ca2+, increased SR Ca2+ and more spontaneous Ca2+ releases from the SR. 
Furthermore, electrophysiological studies revealed that the AP is prolonged in Rbm20 KO 
cardiomyocytes. Alternative splicing changes in two Rbm20 target genes, i.e. CamkIIδ and Cacna1c, 
pointed us to the LTCC as the potential culprit for the observed Ca2+ overload in Rbm20 KO 
cardiomyocytes. We recorded ICa,L and show that LTCC activity is substantially increased in Rbm20 KO 
cardiomyocytes. Moreover, blockade of ICa,L with the LTCC-antagonist verapamil completely rescued the 
noradrenaline-induced spontaneous Ca2+ releases from the SR, indicating that increased ICa,L density 
enhances Ca2+ influx and, in turn, causes intracellular and SR Ca2+ overload in Rbm20 KO cells (Figure 5). 
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Our data indicates that this function of Rbm20 likely underlies the increased risk of arrhythmias in 
RBM20 mutation carriers, and therefore this study provides new avenues to investigate the treatability 
of arrhythmias in RBM20 mutation carriers. Furthermore, our findings underscore the necessity for 
careful clinical monitoring of potential electrical disturbances and cardiac arrhythmias in RBM20 
mutation carriers, even during the early stages of the disease. 
 
 
It has been proposed that regulating TTN splicing, by means of modulating RBM20 levels, could be 
beneficial for the heart, especially in the setting of heart failure with preserved ejection fraction 
(HFpEF)13, 30, 31. Methawasin et al. have shown that in heterozygous Rbm20 KO mice beneficial effects of 
more compliant Ttn (i.e. reduction in diastolic chamber stiffness) dominate over disadvantageous effects 
(i.e. depressed end-systolic elastance)13. In a mouse model of HFpEF, these beneficial effects were even 
more pronounced30. However, our current study reveals that although it may be advantageous to 
modulate Ttn splicing to decrease passive stiffness in certain types of heart disease where passive 
stiffness is increased, the effect on other Rbm20 targets must be carefully evaluated. The fact that a 50% 
reduction in Rbm20 levels (i.e. in Rbm20+/- mice) already induces a clear shift in CamkIIδ towards the δ- 
A and δ-9 isoform, with concomitant Ca2+ handling abnormalities, argues for careful examination of using 
RBM20 modulation as a therapeutic option. The exquisite sensitivity of isoform expression by levels of 
RBM20 was also observed in the study of Maatz et al. who showed that RBM20 levels closely correlate 
with the extent of splicing in RBM20 targets such as TTN, CAMK2D, RYR2 and LDB3.6 
 
The observed increase in LTCC density and intracellular Ca2+ overload in Rbm20 KO hearts can not be 
explained by an underlying cardiomyopathy since it sharply contrasts to what is generally observed in 
DCM or heart failure, where LTCC density is either unaltered or reduced, and intracellular Ca2+ and SR 
Ca2+ content are decreased32, 33. Therefore, it is very unlikely that the Ca2+ handling abnormalities in the 
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Rbm20 KO hearts are secondary to the DCM, but rather directly caused by the loss of Rbm20 and its 
effects on splicing of Ca2+ handling genes. We show that ICa,L inhibition with verapamil in Rbm20-/- 
cardiomyocytes decreases the number of pro-arrhythmic Ca2+ releases, and this suggests that verapamil 
may be used as therapy for RBM20 mutation carriers to reduce their arrhythmia burden. Verapamil is a 
class IV anti-arrhythmic agent, and acts by blocking voltage-dependent Ca2+ channels. It is currently used 
to treat hypertension and migraines, but is contra-indicated in the treatment of general heart failure. 
This is due to the fact that verapamil has a negative inotropic effect since it lowers intracellular Ca2+, 
which in most forms of heart failure is already decreased32, 33. In addition, the few small clinical trials in 
heart failure patients that have been carried out, have not shown a beneficial effect of this drug34. 
However, since in heart failure cardiac Ca2+ cycling is generally diminished, it is not surprising that 
verapamil was not found to have a beneficial effect (it could even worsen cardiac function by further 
decreasing intracellular Ca2+ and thereby contractility). Since cardiac Ca2+ transients are increased in 
RBM20 mutation carriers, treatment with verapamil could be beneficial for this subgroup of heart failure 
patients. Besides verapamil, other ways to therapeutically decrease intracellular Ca2+ and SR Ca2+ 
content, might be worthwile to explore in RBM20 mutation carriers as well. 
 
 
In recent years, the importance of alternative splicing, and how abnormal splicing contributes to heart 
disease, has become increasingly clear35, 36. Several splicing factors, including Rbm20, Rbm24, Rbfox, and 
SF3B1, were shown to have critical roles in the developing or adult heart5, 37-39. Interestingly, the isoform 
switch in CamkIIδ to the δ-A and δ-9 isoform that we observed in the Rbm20 KO mice is also seen after 
cardiac-specific deletion of yet another splicing factor, ASF/SF2, leading to similar changes in cardiac Ca2+ 
handling21. Furthermore, the same study also provided evidence that transgenic overexpression of 
CamkIIδ-A alone phenocopies the Ca2+ handling defects observed in the ASF/SF2 KO mice, indicating that 
the shift in CamkIIδ isoforms largely underlies the Ca2+ handling defects in the ASF/SF2 KO21. Surprisingly, 
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a complete loss of CamkIIδ in mycocytes also results in an increase in ICa,L, albeit to a lesser extent (15- 
18% in CamkIIδ KO vs 82% in Rbm20 KO)40. However, opposite to what is seen in ASF/SF2 KO (and in 
Rbm20 KO), CamkIIδ KO cardiomyocytes have decreased intracellular Ca2+ and SR Ca2+ content. Overall, 
these studies show that changes in CamkIIδ isoforms are more detrimental than complete loss of 
CamkIIδ15, 18, 21, 41, 42. Particularly the observation that transgenic overexpression of the δ-A isoform of 
CamkIIδ phenocopies the Ca2+ handling defects that we observed in the Rbm20 KO hearts, suggests that 
the isoform switch in CamKIIδ in Rbm20 KO hearts is largely responsible for the Ca2+ defects. We did not 
observe increased phosphorylation of Thr498 in Cacnb2 (a reported CamKIIδ target16) in Rbm20 KO 
hearts, indicating that phosphorylation of this specific residue is not the reason why the LTCC is more 
active. Therefore, how increased expression of CamkIIδ-A increases L-type calcium current, be it through 
increased LTCC phosphorylation16, 17 or a different mechanism, remains to be investigated. 
 
Naturally, we can not exclude the contribution of Rbm20-dependent splicing events in RyR2, Cacna1c, 
Ncx1, and Scn5a to the Ca2+ phenotype, but the function of these splice isoforms are less well-studied. It 
is for example known that inclusion of the Rbm20-dependent 24-bp exon in RyR2 targets RyR2 to an 
intranuclear Golgi-apparatus, instead of the SR22. Reduced RyR2 in the SR could also impact cardiac Ca2+ 
handling, but the contribution of this differential splice event in Rbm20 KO cardiomyocytes remains to  
be determined. The same holds true for the splicing changes in Cacna1c, Ncx1, and Scn5a, as these could 
also impact Ca2+ handling, either directly or indirectly. However, we did not observe hyperpolarization of 
the LTCC due to increased inclusion of exon 9* in Cacna1c, as was previously reported24, indicating that 
this specific splicing event does not affect the LTCC in mouse cardiomyocytes, or that the increase was 
not sufficient to induce the hyperpolarization (Fig 3G). 
18  
Familial DCM is often caused by mutations in sarcomeric genes4, but in RBM20 mutation carriers the 
DCM is caused by a dysfunctional splicing factor, which makes the disease phenotype likely much more 
complex. Dysfunctional RBM20 affects a multitude of genes, such as sarcomeric and Ca2+ handling genes, 
which together are responsible for the disease phenotype in RBM20 mutation carriers. In that sense, it is 
likely that the disease (and arrhythmogenic) phenotype is only partly explained by the CamkIIδ-LTCC 
pathway, and that other factors also contribute. The splicing changes in CamkIIδ likely also affect other 
target proteins, such as PLB or RyR2, and although we did not observe a difference in CamkII-dependent 
phosphorylation of RyR2 on S2815, we cannot rule out that altered phosphorylation status of these 
targets might have contributed to the calcium disturbances. Additionally, loss of the nuclear CamKIIδ-B 
isoform in the Rbm20 KO hearts may lead to hampered nuclear export of histone deacetylases, thereby 




There are some limitations to this study. First, with regard to the clinical data, it must be noted that we 
had access to only a limited number of RBM20 and TTN mutation carriers, and therefore these results 
can merely serve as an indication of the arrhythmia burden of these two groups of DCM patients. It will 
be important to validate these findings in larger cohorts. In addition, although it is likely that TTN is 
misspliced in the RBM20 mutation carriers, we do not have acces to their cardiac tissue, and could not 
validate that TTN is similarly affected in all patients. Therefore, we need to be cautious about the 
conclusions drawn from this table. Nevertheless, the table shows that dysfunctional TTN does not lead to 
an arrhythmogenic phenotype, while dysfunctional RBM20 does. In addition, the occurrence of sustained 
VT/VF in 50% in RBM20 mutation carriers indicates that RBM20 mutations carriers have an arrhythmia 
burden comparable to LMNA mutation carriers, which are known to have an arrhythmogenic 
phenotype4. 
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Second, there are differences between the human RBM20 mutation carriers and our Rbm20 KO mouse 
model. The mouse model represents a true loss-of-function (and 50% Rbm20 protein levels in the 
heterozygotes), while most human RBM20 mutation carriers have a missense mutation in the RNA 
binding region in only one allele. It is conceivable that these missense mutations do not lead to protein 
instability or nonsense mediated decay, but rather to disruption of RBM20 binding to RNA through 
potentially dominant-negative mechanisms. Mouse models in which specific human RBM20 mutations 
are introduced are awaited with great interest to further study the underlying pathophysiological 
mechanism. Third, the electrophysiological properties of human and mouse cardiomyocytes are not 
entirely similar. For example, the differences in potassium currents between human and mouse may 
explain why we did not observe QTc prolongation in RBM20 mutation carriers, while we did see QTc 
prolongation in Rbm20-/- mice43. However, the basic calcium handling machinery is comparable, and 
human iPSC-CM derived from an RBM20 mutation carrier show similar calcium handling abnormalities9. 
 
In conclusion, much of the research regarding RBM20-induced cardiomyopathy has focussed on TTN, but 
aberrant TTN splicing only partly explains the clinical characteristics of RBM20 mutation carriers. Here, 
we provide evidence that Rbm20 controls Ca2+ handling by regulating the activity of ICa,L. This function of 
Rbm20 likely underlies the increased risk of arrhythmias in RBM20 mutation carriers, and therefore we 
provide proof-of-concept of a potential therapy to relieve RBM20 mutation carriers from their 
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Table 1. Comparison of patients with RBM20 mutations to patients with TTN mutations. 
 
 
Parameter RBM20 (n=18) TTN (n=22) P value 
Patient characteristics 
Age (yrs) 42 ± 14 45 ± 16 0.486 
Male sex, n (%) 8 (44) 9 (41) 0.923 
Proband, n (%) 11 (61) 14 (64) 0.870 
FH SCD, n (%) 13 (72) 8 (36) 0.052 
Follow-up (months) 71±65 62±34 0.098 
Cardiac function 
LVEF (%) 37 ± 17 37 ± 13 0.933 
LVEDD (mm) 60 ± 11 59 ± 9 0.828 
LVEDV (ml) 269 ± 92 246 ± 73 0.447 
LVEDV index (ml/BSA) 132 ± 32 120 ± 7 0.201 
ECG parameters 
Heart rate (bpm) 72 ± 20 71 ± 13 0.884 
PR (ms) 149 ± 14 165 ± 29 0.056 
QRS (ms) 101 ± 20 98 ± 19 0.570 
QTc (ms) 414 ± 34 411 ± 40 0.828 
Arrhythmias 
Atrial fibrillation, n (%) 6 (33) 8 (36) 0.870 
Non-sustained VT, n (%) 5 (28) 7 (32) 0.945 
Sustained VT or VF, n (%) 8 (44) 1 (5) 0.006 
ICD treatment, n (%) 11 (61) 2 (9) 0.002 
Pharmacological therapy 
Beta-blocker, n (%) 14 (78) 14 (64) 0.533 
ACE inhibitor or ATII antagonist, n (%) 12 (67) 15 (68) 0.812 
MRA, n (%) 8 (44) 8 (36) 0.846 
Diuretics, n (%) 7 (39) 6 (27) 0.659 
Digoxin, n (%) 1 (6) 3 (14) 0.613 
Class III antiarrhythmic drug, n (%) 2 (11) 4 (18) 0.673 
 
ACE, angiotensin converting enzyme; ATII, angiotensin receptor II; FH SCD, family history of sudden 
cardiac death <45 years; ICD, internal cardioverter defibrillator; LVEF, left ventricular ejection fraction; 
LVEDD, left ventricular end-diastolic diameter; LVEDV, left ventricular end-diastolic volume; LVEDV index, 
left ventricular end-diastolic diameter indexed to body surface area (BSA); MRA, mineralocorticoid 
receptor antagonist; QTc, heart-rate corrected QT interval; VT, ventricular tachycardia; VF, ventricular 
fibrillation. N indicates number of patients. Data are presented as mean ± standard deviation (SD). To 
test for statistically significant differences between the groups, two-tailed Students t-test was used for 
continuous variables and Fisher exact test or χ2 test for categorical variables. 
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Figure 1: Characterization of Rbm20 KO mice. A. Gene targeting strategy of Rbm20 KO mice. Mice carrying the 
targeted allele were crossed with Flp-mice to remove the LacZ and neomycin cassette and subsequently with CMV- 
Cre mice to genetically delete exon 4 and 5 of Rbm20. B-D. qPCR in hearts of wildtype (n=6), Rbm20 +/- (n=8), and 
Rbm20 -/- (n=8) mice of respectively Rbm20, ANF, and BNP. E. RT-PCR analysis of Ttn and Ldb3 splicing in the hearts 
of 3 wildtype, 3 Rbm20 +/-, and 3 Rbm20 -/- mice. Largest PCR product of TTN represents the inclusion of additional 
PEVK exons, indicative of the N2BA-G isoform. F. Heart weight/body weight ratios of wildtype (n=6), Rbm20 +/- 
(n=8), and Rbm20 -/- (n=8) mice. G-I. Echocardiographic analysis of wildtype (n=7), Rbm20 +/- (n=9), and Rbm20 -/- 
(n=8). LVESD, Left Ventricular End-Systolic Diameter. J-K. Surface electrocardiograms of wildtype (n=7), Rbm20 +/- 
(n=9), and Rbm20 -/- (n=8) mice. QTc, heart-rate corrected QT interval. L. H&E and Picrosirius Red staining of 
wildtype, Rbm20 +/- , and Rbm20 -/- heart sections. M. Quantification of fibrosis in wildtype (n=6), Rbm20 +/- 
(n=6), and Rbm20 -/- (n=8) hearts. All analyses were done in 25 weeks old mice. One-way ANOVA with Least 
Significance Difference (LSD) post-hoc correction was used to test for statistical significance. * means p < 0.05 vs 
wildtype, # means p < 0.05 vs Rbm20 +/-. 
 
 
Figure 2. Rbm20 regulates splicing of Ca2+ and ion handling genes. A. Two biological categories were identified in 
the most enriched process (cardiac muscle contraction) after gene ontology enrichment analysis (DAVID) of 
differentially spliced genes in Rbm20 KO hearts: sarcomeric genes and ion handling genes. *Cacna1c splicing 
changes did not pass the adjusted p-value in this n=3 experiment, but has previously been shown to be an Rbm20- 
target5. B. RT-PCR validation of differential splicing events in CamKIIδ, RyR2, Scn5a, Cacna1c in hearts of wildtype, 
Rbm20 +/-, and Rbm20 -/- hearts. C. Western blot of CamkIIδ in hearts of wildtype, Rbm20 +/-, and Rbm20 -/- mice. 
D. Immunohistochemistry of CamkIIδ (red) in hearts of wildtype and Rbm20 -/- mice. Cacnb2 (green) was used to 
stain LTCCs, DAPI (blue) was used to stain nuclei. Scale bar = 20 μm. The analyses were done on hearts of 25 weeks 
old mice. E. qPCR of Rbm20 mRNA levels in NRCM 48h after GapmeR-mediated knockdown of Rbm20. SCR = 
Scrambled, KD = Knockdown F. RT-PCR of Ttn, CamkIIδ, and RyR2 splicing after Rbm20 knockdown in NRCM. G. 
DeltaPSI-plots of CamkIIδ and RyR2 of a DCM-patient (black line) and an RBM20 mutation carrier (red line) as 
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compared to the mean of 10 healthy control hearts. PSI = Percentage Spliced In. Two-tailed Students t-test was 
used to test for statistical significance. 
 
 
Figure 3. Rbm20 KO cardiomyocytes display action potential prolongation and increased L-type calcium current. 
 
A. Typical action potentials of wildtype and Rbm20 -/- cardiomyocytes. B. Action potential duration at 20%, 50%, 
and 90% of repolarization of wildtype and Rbm20 -/- cardiomyocytes. C. Action potential amplitude (APA) and 
resting membrane potential (RMP) of wildtype and Rbm20 -/- cardiomyocytes. D. Average Vmax of wildtype and 
Rbm20 -/- cardiomyocytes. E. Left panel, representative recordings of current traces following depolarizing pulses 
from -60 to 0 mV. Right panel, normalized currents. F. Average current-voltage relationships of ICa,L. G. Activation 
and inactivation relationships. Solid lines are Boltzmann fits. Inset, Voltage clamp protocol. Cells were isolated from 
8-12 weeks old mice. Unpaired t-test or Two-Way Repeated Measures ANOVA followed by pairwise comparison 
using the Student-Newman-Keuls test were used to test for statistical significance. 
 
 
Figure 4. Rbm20 KO cardiomyocytes display intracellular Ca2+ overload and are prone to spontaneous Ca2+ 
releases. A. Representative calcium transients of wildtype, Rbm20 +/-, and Rbm20 -/- cardiomyocytes. B. Average 
of diastolic calcium in wildtype (n=23), Rbm20 +/- (n=21), and Rbm20 -/- (n=18) cardiomyocytes at 6 Hz. C. Average 
peak transient in wildtype (n=23), Rbm20 +/- (n=21), and Rbm20 -/- (n=18) cardiomyocytes at 6 Hz. D. Average SR 
calcium load in wildtype (n=20), Rbm20 +/- (n=16), and Rbm20 -/- (n=18) cardiomyocytes. E. Average number of 
spontaneous Ca2+ releases during 10 seconds after stimulation at 6 Hz was stopped, with and without 50 nM 
Noradrenaline in wildtype, Rbm20 +/-, and Rbm20 -/- cardiomyocytes, and in Rbm20 -/- cardiomyocytes treated 
with 1 μM verapamil. Cells were isolated from 4-5 different wildtype, Rbm20 +/-, and Rbm20 -/- mice of 8-12 weeks 
of age. One-way ANOVA with LSD posthoc correction (B-D) and Mann-Whitney U test (unpaired samples) or 
Wilcoxon rank test (paired samples) (E) were used to test for statistical significance. * means p < 0.05 vs wildtype or 
vs Rbm20 -/- (in case of verapamil treatment). 
 
 
Figure 5. Proposed model of how Rbm20 deficiency leads to pro-arrhythmic spontaneous Ca2+ releases. 
27  
Rbm20 deficiency increases inclusion of exon 15 and 16 in CamkIIδ, resulting in the expression of the CamkIIδ-A 
isoform. CamkIIδ-A is preferentially localized at the t-tubules21, where the LTCC is also localized. An increased ICa,L 
subsequently enhances intracellular [Ca2+] and SR Ca2+ content. The increase in SR Ca2+ content drives spontaneous 
Ca2+ releases from the SR. Inhibition of ICa,L with the LTCC-antagonist verapamil decreases the number of 
spontaneous Ca2+ releases. LTCC, L-type calcium channel. p-LTCC, phosphorylated L-type calcium channel. RyR2, 
Ryanadine Receptor 2. SR, sarcoplasmic reticulum. N, nucleus. ICa,L, L-type calcium current. 
